# MARCHF4

## Overview
MARCHF4, or Membrane Associated Ring-CH-Type Finger 4, is a gene that encodes a protein belonging to the RING-CH family of E3 ubiquitin ligases. These proteins are characterized by their role in tagging specific proteins for degradation via the ubiquitin-proteasome system, a critical process in maintaining cellular homeostasis. The MARCHF4 protein is involved in various cellular processes, including the regulation of membrane protein turnover and modulation of immune responses. Recent studies have highlighted its potential role in cancer biology, particularly in the context of chemotherapeutic resistance and epithelial-mesenchymal transition (EMT) in prostate cancer cells (Wang2022Targeting). The gene's expression is influenced by factors such as stromal cell-derived epiregulin, which activates key signaling pathways, suggesting its involvement in the adaptive resistance mechanisms of cancer cells (Wang2022Targeting).

## Clinical Significance
MARCHF4 is implicated in cancer progression and resistance to chemotherapy. Overexpression of MARCHF4 in prostate cancer cell lines, such as PC3 and DU145, enhances cell viability under mitomycin C treatment, indicating a role in chemotherapeutic resistance. This overexpression is associated with a pattern of epithelial-mesenchymal transition (EMT), although no transcriptional changes were observed in other malignancy-related factors. MARCHF4 reduces apoptotic activity in response to genotoxic stress, contributing to cancer cell resistance to chemotherapy (Wang2022Targeting).

The gene is also upregulated in cancer cells in response to stromal cell-derived epiregulin (EREG), which activates pathways like Akt/mTOR and MEK/ERK. This suggests that MARCHF4 may mediate resistance in cancer cells driven by EREG. Targeting EREG with monoclonal antibodies has been proposed to minimize cancer resistance in treatment-damaged tumor microenvironments (Wang2022Targeting).

While the literature on MARCHF4 and cancer progression is limited, its involvement in malignant progression and drug resistance is highlighted. The specific role of MARCHF4 in other diseases or conditions remains unclear, but its expression alterations are associated with poor prognosis in cancer (Wang2022Targeting).


## References


[1. (Wang2022Targeting) Changxu Wang, Qilai Long, Qiang Fu, Qixia Xu, Da Fu, Yan Li, Libin Gao, Jianming Guo, Xiaoling Zhang, Eric W.-F. Lam, Judith Campisi, and Yu Sun. Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance. Oncogene, 41(45):4941â€“4959, October 2022. URL: http://dx.doi.org/10.1038/s41388-022-02476-7, doi:10.1038/s41388-022-02476-7. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-022-02476-7)